Bleeding during oral anticoagulant therapy: Warning against a greater hazard;Sangramento durante a anticoagulação oral: Alerta sobre um mal maior

Arquivos Brasileiros de Cardiologia

Volumn 93, Issue 2, 2009, Pages 174-179

  De Lavítola, Paulo Lara ^a   Spina, Guilherme Sobreira ^a   Sampaio, Roney Orismar ^a   Tarasoutchi, Flávio ^a   Grinberg, Max ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anticoagulants; Atrial fibrillation; Hemorrhage; Mitral valve stenosis

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH HAZARD; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE PROLAPSE; MITRAL VALVE PROSTHESIS; MITRAL VALVE STENOSIS; PROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAZIL; CHI-SQUARE DISTRIBUTION; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; GENITAL DISEASES, FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; KIDNEY CALCULI; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERENCE VALUES; THROMBOEMBOLISM; URINARY BLADDER DISEASES; UTERINE HEMORRHAGE;

EID: 70350716097     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2009000800017     Document Type: Article

References (15)

1. Coulshed N, Epstein EJ, Mckendrick CS, Galloway RW, Walker E. Systemic embolism in mitral valve disease. Br Heart J. 1970; 32: 26-34.
2. The Framinghan study. Neurology. 1978; 28: 973.
3. Shetty HGM, Woods F, Routledge PA. The pharmacology of oral anticoagulants: implications for therapy. J Heart Valve Dis. 1993; 2: 53-62.
4. Levine MN, Rakob G, Beyth RJ, Kearan C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (3 Suppl): 287S-310S. (Pubitemid 39297958)
5. Bussey HI, Chiquette EE. Control of Warfarin treatment and problems with the International Normalized Ratio. Clin Appl Thromb Hemost. 1997; 3: S16-S23.
6. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J. 1964; 1: 209-212
7. Butchart EG. Thrombogenesis and anticoagulation in heart valve disease: towards a rational approach. [Editorial]. J Heart Valve Dis. 1993; 2: 1-6.
8. Levine HJ, Pauker SG, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest. 1995; 108: 360S-370S.
9. Oden A, Fahlen M, Hart RG. Optimal INR for preventions of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res. 2006; 117: 493-499 (Pubitemid 43326133)
10. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, et al. Managing oral anticoagulant therapy. Chest. 2001; 119: 225-385.
11. Aronow WS, Ahn C, Kronzon I, Gutstein H. Effect of warfarin versus aspirin on the incidence of new thromboembolic stroke in older persons with chronic atrial fibrillation and abnormal and normal left ventricular ejection fraction. Am J Cardiol. 2000; 85: 1033-1035 (Pubitemid 30176152)
12. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of lhe lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335: 540-546
13. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001; 119: 108S-121S.
14. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity and risk for intracranial hemorrhage among patients Warfarin for atrial fibrillation. Ann Intern Med. 2004; 141: 745-752
15. Sampaio RO, Grinberg M. Cardiopatia valvar na mulher. Rev Soc Cardiol Estado de São Paulo. 1996; 6: 757-762